our tenants words speak for themselves

iGene London Limited. (an INFOVALLEY Company)

iGene London Limited is a subsidiary of iGene (Malaysia) Sdn. Bhd. (an INFOVALLEY Company), largely involved in the development of next generation technologies based on life sciences. INFOVALLEY Group of Companies (www.infovalley.net.my) is focused on healthcare and forensic market, primarily leveraging on high impact biotechnologies and advance medical informatics. Built on its strength in research and development since Year 2000, the London subsidiary was incorporated in March 2011 to expand its R&D capabilities and capacity while focusing on the development of core technologies with global impact.

iGene London’s facility at QMB will serve the R&D and commercialization activities across Europe. It will function as a key R&D Facility to broaden the application of high definition visualization technologies and semantic engineering for use in forensic examination and medical education.  

iGene is currently in discussion with the medical and technical staff of the Bradford Public and Forensic Mortuary in West Yorkshire. The partnership is expected to provide exciting development in post-mortem examination using the Digital Autopsy technique, education, training, research and development of other new technologies.

IGene's thoughts on the QMB Innovation Centre's support:

"The team has spent several years working in academic surroundings and we are extremely excited to move into the Innovation Centre. It marks a real milestone in terms of commercial development of the Company and QMB, being so close to the City and with such excellent facilities seemed the ideal choice for us. We have state of the art laboratories for our research as well as space for growth and support in developing the business – vital for early stage companies.

I look forward to moving in and getting to know the other companies in the Innovation Centre – I’m confident it will be an important hub of biotechnology in London and we are excited to be a part of it.”

Professor Peter Vanezis OBE, the Head of the Scientific Advisory Board of iGene.

Barts and the London School of Medicine and Dentistry

Barts and the London School of Medicine and Dentistry, is a world-class research institution with expertise in the challenging diseases of the modern world. There has been major investment in a full range of clinical research facilities, adjacent to the redeveloped Barts and the London NHS Trust, the largest hospital development in Europe.

The medical school has invested heavily in biological service units, genomics,
proteomics, advanced imaging, flow cytometry and cell sorting together with the
technical expertise to manage these facilities. Researchers in the Innovation Centre
will have access to these facilities subject to capacity. There is also a supply of
talented and highly qualified technical staff, both from the NHS and graduates of
Queen Mary University of London.

Staff in the QMB Innovation Centre who wish to participate in the academic life of the school of medicine and dentistry can apply for honorary contracts, giving access to research and logistical services such as seminars, local library and e-resources, undergraduate student research projects, MSc and PhD student supervision, opportunities for teaching, and to be part of the vibrant research culture at one of the top institutions in the UK.

MediWiSe (Medical Wireless Sensing Ltd.)

"MediWise" (Medical Wireless Sensing) designs, develops and tests innovative medical devices based on Microwave Medical Imaging (MMI) technology for non-invasive, early stage screening of cancer. MediWiSe’s expertise is at the forefront of new technological developments and is aiming to become a leader in the new generation of medical imaging. MediWise's vision is to harness cutting-edge innovation to develop safer and affordable solutions for better patient care. The core of our patent pending technology is based on a novel and original use of low-power microwaves in combination with advance material technology (Metamaterials) for high accuracy, non-invasive medical imaging. The proposed system is radiation free and thus can offer a safer and cheaper alternative to conventional medical imaging methods.

MediWise's thoughts on the QMB Innovation Centre's support:

"The QMB Innovation Centre has been a pivotal ally. They provide strategic guidance, access to investors, mentors, and a ready-made network of contacts, specialised training, affordable space, and professional services at reduced rates, being inside the QMB incubator makes us realise that we not alone. Thank you!"

George Palikaras, Founder and CEO of MedWise

Duvas Technologies

DUVAS is an acronym for Differential UltraViolet Absorption Spectroscopy. It is a highly flexible cost effective family of intelligent portable, mobile and fixed sensors using closed path spectroscopy, capable of detecting multiple pollutants simultaneously at ppb level.

Duvas Technologies, is a technology company, spun out of Imperial College in 2008 by Verdetech Investments Limited and Imperial Innovations. The Company produces a proprietary multi-species gas analyser based upon proven Ultra Violet spectroscopy with proprietary technology and know-how.  The product’s initial market is addressing Air Quality Management (AQM), although it also has applications in security/emergency response and oil and gas.

DUVAS Technologies thoughts on the QMB Innovation Centre's support:

“Duvas Technologies is delighted to be moving its operations to the state-of-the-art facilities at the QMB Innovation Centre.  We believe that the facilities on offer, and the location of QMB very close to the City of London, will offer a great platform for Duvas as it moves into its next stage of commercial development.”

Jacqui Nelson, CEO of Duvas

Ferlin Medical

Ferlin Medical Ltd has developed the technology to proof-of-concept stage for a painless, non-invasive monitoring system for blood glucose. Unlike existing solutions this device will change people’s apprehensions towards blood sugar monitoring.?

The company is a spin-out from a successful medical device company which developed three discrete cancer related clinical applications that are now undergoing clinical trials.

Activiomics

Activiomics Ltd has been set up to commercialise a technology which enables the pharmaceutical and biotechnology industry to identify biomarkers and better select new drugs for diseases such as cancer, autoimmunity and diabetes thereby helping to reduce their time to market. Activiomics partners with the pharmaceutical and biotechnology industry to generate high value information using its novel TIQUAS platform which has significant advantages over existing phosphoproteomics techniques.

Neurotex

Neurotex Ltd was established in June 2006 with £250,000 seed funding from the Kinetique Biomedical Seed Fund. The company will commercialise a modified wild silk, known as Spidrex® for the repair of damaged nerves.

It is expected that the product will lead to treatment for damaged nerves, such as those caused by a knife wound to the wrist, and may eventually lead to treatments for repairing damaged spinal cords.

DegraSense

(awaitng logo) DegraSense Ltd has been set up to commercialise protease biosensor technology. There are a range of potential industrial applications for the biosensor technology but the initial focus is on improving the diagnosis and treatment of periodontal disease, estimated to cost the NHS £250 million per year. DegraSense plans to develop a low cost, disposable biosensor that will enable a dentist to identify areas of active inflammation immediately prior to treatment. This will allow more efficient targeting of expensive and labour intensive surgical treatment for patients with periodontitis.

Vaxome

Vaxome Ltd is developing a novel vaccine technology that has the potential to address some major unmet needs in the field of immunotherapy.

The technology comprises an improved antigen presentation and delivery system for specifically stimulating T cell-medicated immune responses. The technology is applicable to the development of immunotherapies for chronic viral disease (such as HIV, HSV, HCV) and cancer where stimulation of cellular responses, particularly CD8+ cytotoxic T lymphocytes (CTLs) are important for clearance of virally infected cells and tumour cells?.

Stealthyx Therapeutics

Stealthyx Therapeutics Ltd has been established to commercialise a novel approach to disease-specific delivery of biological therapeutic molecules. This Prothyx™ fusion protein technology delivers clinical benefits by increasing the therapeutic window where drugs can be used safely and reducing the re-administration interval.

Stealthyx’s drug delivery platform has applications in a variety of diseases that can be treated with biological molecules, including inflammatory diseases such as rheumatoid arthritis, cancer, cardiovascular disease, diabetes and infection. It is intended that drug delivery applications will be developed collaboratively with biopharmaceutical companies that provide the therapeutic component.

Stealthyx’s programme of research has to date been funded through the Kinetique Biomedical Seed fund, the National Multiple Sclerosis Society (USA), the EU FP7 programme, and a Translational Award from the Wellcome Trust.

Dice Engine

Dice Engine is producing a new innovative engine technology, which claims to produce close to twice the power of a conventional four stroke engine (suitable for cars, motorbikes, planes and boats, etc) of similar mass and dimensions, which will have huge fuel and manufacturing cost saving implications.

The intellectual property holding Company behind this concept is teaming up with Queen Mary University of London (QMUL) and Advanced Engine Research Ltd (AER).

DocBox

Docbox is a service and technology based healthcare initiative that provides a new innovative way for the general public to consult with a physician. MDB Medical Services LTD operates Docbox Health Systems which combine the latest telemedicine and diagnostic technologies in order to allow our network of physicians to directly interface with the patient in any location and at any time.